GSK's Otilimab Goes Head-To-Head To Crack Rheumatoid Arthritis

 
• By John Davis

GlaxoSmithKline is exploring a potential new way of tackling rheumatoid arthritis in just-started Phase III studies which could shake up a disease sector that is already attracting interest from other big pharma companies.  

Old_Hands
Rheumatoid arthritis can cause painful deformities. • Source: Shutterstock

More from Clinical Trials

More from R&D